SynAct Pharma
17.52 SEK
Less than 1K followers
SYNACT
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for SynAct Pharma
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 7.99 | 43.70 | 140.46 | 80.76 | 8.75 | 8.97 | 22.60 |
| Shares | 14.9 | 24.7 | 26.2 | 29.9 | 35.9 | 46.5 | 53.3 |
| Market cap | 118.9 | 1,081.2 | 3,680.8 | 2,416.3 | 314.1 | 416.8 | 1,205.3 |
| Enterprise value | 115.3 | 1,066.6 | 3,659.8 | 2,310.2 | 252.3 | 357.4 | - |
| EV/S | - | - | - | - | - | - | - |
| EV/EBITDA | neg. | neg. | neg. | neg. | neg. | neg. | - |
| EV/EBIT | neg. | neg. | neg. | neg. | neg. | neg. | - |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 8.80 | 68.14 | 176.37 | 19.10 | 1.78 | 1.95 | 7.08 |
| P/S | - | - | - | - | - | - | - |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 56.7 % | 73.5 % | 54.4 % | 88.7 % | 77.3 % | 79.2 % | 77.2 % |
| Gearing ratio | - | - | 14.8 % | 1.6 % | 0.4 % | 0.9 % | 0.7 % |